Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma

Blood

Volumn 91, Issue 12, 1998, Pages 4677-4685

  Elenitoba Johnson, Kojo S J ^b   Gascoyne, Randy D ^b   Lim, Megan S ^b   Chhanabai, Mukesh ^b   Jaffe, Elaine S ^b   Raffeld, Mark ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P15; PROTEIN P16; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; CHROMOSOME 9P; CHROMOSOME DELETION; CLINICAL ARTICLE; FOLLICULAR LYMPHOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 0031839956     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.12.4677.412k40_4677_4685     Document Type: Article

References (32)

1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Garter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 84:1361, 1994
2. Cullen MH, Lister TA, Brearley RI, Shand WS, Stansfeld AG: Histologic transformation of non-Hodgkin's lymphoma: A prospective study. Cancer 44:645, 1979
3. Garvin AJ, Simon RM, Osborne CK, Merrill J, Young RC. Berard CW: An autopsy study of histologic progression in non-Hodgkin's lymphoma. 192 cases from the National Cancer Institute. Cancer 52:393, 1983
4. Hubbard SM, Chabner BA, De Vita VT, Simon R, Berard CW, Jones RB, Garvin AJ, Canellos GP, Osborne CK, Young RC: Histologic progression in non-Hodgkin's lymphoma. Blood 59:258, 1982
5. Acker B, Hoppe RT, Colby TV, Cox RS, Kaplan HS, Rosenberg SA: Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1:11, 1983
6. Oviatt DL, Cousar JB, Collins RD, Flexner JM, Stein RS: Malignant lymphomas of follicular center origin in humans. V. Incidence, clinical features and prognostic implications of transformation of small cleaved cell nodular lymphoma. Cancer 53:1109, 1984
7. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ: Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41:899, 1985
8. Tsujimoto Y, Finger LR, Yunis JJ, Nowell PC, Croce CM: Cloning of the chromosome breakpoint of neoplastic B-cells with the t(14;18) chromosome translocation. Science 226:1097, 1984
9. Weiss LM. Warnke RA, Sklar J, Cleary ML: Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 317:1185, 1987
10. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ: Bcl-2 immunoglobulin transgenic mice demonstrate extended B-cell survival and follicular lymphoproliferation. Cell 57:79, 1989
11. Hockenbery D, Nunez G, Milliman C, Schreiber RD. Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334, 1990
12. Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M: Multiple recurrent genomic defects in follicular lymphoma. Apossible model for cancer. N Engl J Med 316:79, 1987
13. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeid M: p53 mutation is associated with progression in follicular lymphomas. Blood 82:1995, 1993
14. Yano T, Jaffe ES, Longo DL, Raffeid M: MYC rearrangements in histologically progressed follicular lymphomas. Blood 30:758, 1992
15. Kamb A, Gruis NA. Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III. Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436, 1994
16. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond) 366:704, 1993
17. Otsuki T, Clark HM, Wellman A, Jaffe ES, Raffeid M: Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 55:1436, 1995
18. Dreyling MH, Bohlander SK, Le Beau MM, Olopade OI: Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood 86:1931, 1995
19. Gombart AF, Morosetti R, Miller CW, Said JW, Koeffler HP: Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas. Blood 86:1534, 1994
20. Zhuang Z, Bertheau P, Emmert-Buck MR, Liotta L, Gnarra J, Linehan WM, Lubensky IA: A new microdissection technique for archival DNA analysis of specific cell populations in lesions less than one millimeter. Am J Pathol 146:620, 1995
21. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Bucler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D: Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat Genet 11:210, 1995
22. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56:3630, 1996
23. Cairns P, Tokino K, Eby Y, Sidransky D: Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res 54:1422, 1994
24. Olopade OI, Pomykala HM, Hagos F, Sveen LW. Espinosa R, Dreyling MH, Gursky S, Stadler WM, Le Beau MM, Bohlander SK: Construction of a 2.3-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci USA 92:6489, 1995
25. Quesnel B, Preudhomme C, Phillipe N, Vanrumbeke M, Dervite I, Lai JL, Bauters F, Wattel E, Fenaux P: p16 homozygous deletions in acute lymphoblastic leukemia. Blood 85:657, 1994
26. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415, 1994 (letter)
27. Jen J, Harper JW, Bigner S, Bigner DD, Papadopoulous N, Markowitz S, Willson JKV, Kinzler KW, Vogelstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54:6353, 1994
28. Hebert J, Cayuela JM, Berkeley J, Sigaux F: Candidate tumor-suppressor gene MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 84:4038, 1994
29. Dreyling MH, Bohlander SK, Vardiman JR, Olopade OI: CDKN2 deletion is a frequent event in the histologic transformation to diffuse large cell lymphoma. Blood 86:329a, 1995 (abstr, suppl 1)
30. Koduru PRK, Zariwala M, Soni M, Gong JZ, Xiong Y, Broome JD: Deletion of cyclin-dependent kinase 4 inhibitor genes p16 and p16 in non-Hodgkin's lymphoma. Blood 86:2900, 1995
31. van der Riet P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W, Sidransky D: Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54:1156, 1994
32. Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ: Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 13:1867, 1996